|Articles|December 30, 2015
ACRES, ActivMed Focus on Site Accreditation, Standards
ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.
Advertisement
The Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based non-profit organization building a global system for clinical research and ActivMed Practices & Research, Inc., a woman-owned, for-profit, multi-specialty, free standing research organization based in Massachusetts and New Hampshire, announced a strategic alliance. ActivMed will participate in ACRES ongoing Site Accreditation and Standards Initiative (SASI) to improve performance of global research sites through shared standards, accreditation, training and support.
ActivMed participation will start with membership in a Phase III standards domain team involving personnel and professionalism criteria. With access to nearly one million patients in the Northeast region and a full range of clinical research studies (Phase I, II, III, IIIb and IV) performed on an inpatient and outpatient basis, ActivMed will also collaborate with ACRES in the testing of developed standards and processes for ACRES site accreditation work, professional development programs for research staff that can be offered within local communities as well as on line and the development of education and training programs ongoing at reasonable costs.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
3
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
4
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
5